A Validation Study of an Arabic Version of the Brief Pain Inventory and the MD Anderson Symptom Inventory

Principal Investigator: Xin Shelley Wang, M.D., M.P.H.

Common symptoms of cancer and cancer treatment significantly impair the function and quality of life of patients. However, some of them are often under-treated because of lack of a validated instrument. The current status of symptom management for cancer has been studied in some countries, but not in Morocco. The goal of this study is to establish the validation of two symptom assessment instruments and look at symptoms related to cancer and its treatment in Morocco.

Specific Objectives

  • To validate the Arabic version of the Brief Pain Inventory (BPI) utilizing patients with cancer who currently have pain, and thus produce an instrument that is sensitive, reliable and valid for use in future Arabic clinical trials assessing pain (Complete)
  • To validate the Arabic version of the MD Anderson Symptom Inventory (MDASI) in cancer patients with various different types of cancer, who have undergone various treatments, and who have different levels of severity of symptoms other than pain (Complete)


This validation study included a one-time survey of a sample of outpatients and inpatients with both hematological and solid tumor type diseases at the National Institute of Oncology in Morocco.


Instruments included the Brief Pain Inventory (BPI) and the MD Anderson Symptom Inventory (MDASI).

For more information

Contact Xin Shelley Wang, M.D., M.P.H., at swong@mdanderson.org.